The utility of 99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism.

Hdl Handle:
http://hdl.handle.net/10147/207215
Title:
The utility of 99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism.
Authors:
Glynn, N; Lynn, N; Donagh, C; Crowley, R K; Smith, D; Thompson, C J; Hill, A D K; Keeling, F; Agha, A
Affiliation:
Division of Endocrinology, Beaumont Hospital, RCSI Medical School, Dublin 9,, Ireland.
Citation:
Ir J Med Sci. 2011 Mar;180(1):191-4. Epub 2010 Nov 13.
Journal:
Irish journal of medical science
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207215
DOI:
10.1007/s11845-010-0641-9
PubMed ID:
21076888
Abstract:
BACKGROUND: There are conflicting data in the literature about the sensitivity of sestamibi scintigraphy in parathyroid tumour localisation in primary hyperparathyroidism (PHPT). AIM: We aimed to evaluate the overall sensitivity of this modality in parathyroid tumour localisation and to determine clinical and biochemical factors which influence sensitivity of this method. METHODS: We performed a retrospective review of 57 patients with a biochemical diagnosis of PHPT who had sestamibi scintigraphy performed. RESULTS: The sensitivity of sestamibi scanning was 56% in whole group and 63% in those without nodular thyroid disease. Among the patients with confirmed single gland disease (biochemical cure after surgical removal of a single adenoma), sensitivity was 71%. A positive scan was associated with younger age, greater adenoma weight and higher pre-operative serum calcium. Concordance between the sestamibi and neck ultrasonography was 92% accurate in pre-operative tumour localisation. CONCLUSION: Sestamibi scintigraphy was more likely to be positive in younger patients without nodular thyroid disease who have larger parathyroid adenomas with more severe hyperparathyroidism.
Language:
eng
MeSH:
Adenoma/complications/*radionuclide imaging; Adult; Aged; Aged, 80 and over; Female; Humans; Hyperparathyroidism, Primary/*etiology; Male; Middle Aged; Parathyroid Neoplasms/complications/*radionuclide imaging; Radiopharmaceuticals/*diagnostic use; Retrospective Studies; Sensitivity and Specificity; Technetium Tc 99m Sestamibi/*diagnostic use
ISSN:
1863-4362 (Electronic); 0021-1265 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorGlynn, Nen_GB
dc.contributor.authorLynn, Nen_GB
dc.contributor.authorDonagh, Cen_GB
dc.contributor.authorCrowley, R Ken_GB
dc.contributor.authorSmith, Den_GB
dc.contributor.authorThompson, C Jen_GB
dc.contributor.authorHill, A D Ken_GB
dc.contributor.authorKeeling, Fen_GB
dc.contributor.authorAgha, Aen_GB
dc.date.accessioned2012-02-01T10:02:09Z-
dc.date.available2012-02-01T10:02:09Z-
dc.date.issued2012-02-01T10:02:09Z-
dc.identifier.citationIr J Med Sci. 2011 Mar;180(1):191-4. Epub 2010 Nov 13.en_GB
dc.identifier.issn1863-4362 (Electronic)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid21076888en_GB
dc.identifier.doi10.1007/s11845-010-0641-9en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207215-
dc.description.abstractBACKGROUND: There are conflicting data in the literature about the sensitivity of sestamibi scintigraphy in parathyroid tumour localisation in primary hyperparathyroidism (PHPT). AIM: We aimed to evaluate the overall sensitivity of this modality in parathyroid tumour localisation and to determine clinical and biochemical factors which influence sensitivity of this method. METHODS: We performed a retrospective review of 57 patients with a biochemical diagnosis of PHPT who had sestamibi scintigraphy performed. RESULTS: The sensitivity of sestamibi scanning was 56% in whole group and 63% in those without nodular thyroid disease. Among the patients with confirmed single gland disease (biochemical cure after surgical removal of a single adenoma), sensitivity was 71%. A positive scan was associated with younger age, greater adenoma weight and higher pre-operative serum calcium. Concordance between the sestamibi and neck ultrasonography was 92% accurate in pre-operative tumour localisation. CONCLUSION: Sestamibi scintigraphy was more likely to be positive in younger patients without nodular thyroid disease who have larger parathyroid adenomas with more severe hyperparathyroidism.en_GB
dc.language.isoengen_GB
dc.subject.meshAdenoma/complications/*radionuclide imagingen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHyperparathyroidism, Primary/*etiologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshParathyroid Neoplasms/complications/*radionuclide imagingen_GB
dc.subject.meshRadiopharmaceuticals/*diagnostic useen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshSensitivity and Specificityen_GB
dc.subject.meshTechnetium Tc 99m Sestamibi/*diagnostic useen_GB
dc.titleThe utility of 99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism.en_GB
dc.contributor.departmentDivision of Endocrinology, Beaumont Hospital, RCSI Medical School, Dublin 9,, Ireland.en_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.